Clinical trials: Metastatic Disease
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
This is a multicenter, open-label, phase II study to evaluate the safety, tolerability, clinical activity, and pharmacokinetics of ILKN421H in combination with pembrolizumab in participants with locally advanced or metastatic…
- Trial name
- NCT07452224
- Testing
- ILKN421H, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- iLeukon Therapeutics, Inc.
Locally Advanced or Metastatic NSCLC
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic…
- Trial name
- NCT05990127
- Testing
- AK104, Tislelizumab, carboplatin
- Where
- 62 sites in China
- Volunteers
- 642 people
- Sponsor
- Akeso
Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to determine whether S-1 is effective in slowing tumor activity in participants with locally advanced or metastatic pancreatic cancer who have not had chemotherapy.
- Trial name
- NCT00651742
- Testing
- S-1
- Volunteers
- 28 people
- Sponsor
- Taiho Oncology, Inc.
Pancreatic Adenocarcinoma
A Study of MLN0264 in Patients With Pancreatic Cancer
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with advanced or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the pancreas.
- Trial name
- NCT02202785
- Testing
- MLN0264
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 43 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
This is an open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study in patients with advanced solid tumors.
- Trial name
- NCT01170897
- Testing
- PEGPH20
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Halozyme Therapeutics
Locally Advanced/Metastatic Solid Tumors
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants…
- Trial name
- NCT06414460
- Testing
- ISM3412
- Where
- 10 sites in United States, China
- Volunteers
- 146 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Colorectal Cancer
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
This is a Phase Ib, open-label, multicenter, dose-escalation study designed to assess if PRO95780 in combination with two different irinotecan-containing regimens is safe and tolerable in patients with metastatic colorectal…
- Trial name
- NCT00497497
- Testing
- bevacizumab, cetuximab, FOLFIRI regimen
- Volunteers
- 20 people
- Sponsor
- Genentech, Inc.
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06016920
- Testing
- VB10.16, Pembrolizumab
- Where
- 12 sites in France, Germany and 5 more
- Volunteers
- 110 people
- Sponsor
- Nykode Therapeutics ASA
Uterine Neoplasms, Uterine Cervical Neoplasms
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the…
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
- Trial name
- NCT04579380
- Testing
- tucatinib, trastuzumab, fulvestrant
- Where
- 108 sites in United States, Belgium and 6 more
- Volunteers
- 217 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Metastatic Lesions in Vertebral Bodies
The STAR™ Tumor Ablation Registry
Registry collecting data on use of The STAR™ Tumor Ablation System.
- Trial name
- NCT02419703
- Testing
- STAR™ Tumor Ablation System
- Where
- 15 sites in United States
- Volunteers
- 65 people
- Sponsor
- Merit Medical Systems, Inc.
Breast Cancer
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
A longitudinal, non-interventional study with trastuzumab deruxtecan for patients with HER2-low expressing unresectable or metastatic breast cancer in Bulgaria and Slovenia
- Trial name
- EXPLORE (NCT06727227)
- Testing
- trastuzumab deruxtecan
- Where
- 14 sites in Bulgaria, Slovenia
- Volunteers
- 138 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 for injection in combination with glecirasib in the treatment of patients with locally advanced or metastatic non-small cell lung cancer with…
- Trial name
- NCT07827261
- Testing
- BL-B01D1, Glecirasib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Prostatic Neoplasms, Metastatic Hormone-Sensitive Prostate Cancer
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
Prostate cancer is the most common non-skin cancer among men in the United States. For some men, the cancer has already spread to other parts of the body at the time of diagnosis; this is called metastatic hormone-sensitive…
- Trial name
- Double-DARE (NCT07406282)
- Testing
- Darolutamide, Abiraterone acetate, Enzalutamide
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Bayer
Advanced/Metastatic Solid Tumors
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumors.
- Trial name
- NCT03833427
- Testing
- Selumetinib, Pembrolizumab
- Where
- 6 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Cancer
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
This is a phase 2 study. All subjects are patients with locally advanced unresectable or metastatic pancreatic cancer harboring KRAS G12D mutation who have received at least one prior line of systemic therapy.
- Trial name
- NCT07784374
- Testing
- GFH375, GFH276, GFS202A
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Cancer, Carcinoma
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).
- Conditions
- Cancer, Carcinoma, Head and Neck Cancer, Metastases
- Trial name
- NCT00446446
- Testing
- Panitumumab
- Volunteers
- 52 people
- Sponsor
- Amgen
Prostate Cancer Metastatic
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.
- Trial name
- Prospect (NCT01322490)
- Testing
- PROSTVAC-V, PROSTVAC-F, GM-CSF
- Where
- 220 sites in United States, Australia and 14 more
- Volunteers
- 1,297 people
- Sponsor
- Bavarian Nordic
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell…
- Trial name
- MORALE-HN01 (NCT07662720)
- Testing
- axelopran, Pembolizumab
- Volunteers
- 18 people
- Sponsor
- Glycyx Therapeutics
Breast Cancer
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
- Trial name
- BELLE-4 (NCT01572727)
- Testing
- Paclitaxel, BKM120
- Where
- 112 sites in United States, Australia and 20 more
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This open-label, multicenter, Phase IIIb study will assess the safety, tolerability and efficacy of a combination therapy of intravenous (IV) pertuzumab (Perjeta), trastuzumab (Herceptin) SC, and taxane chemotherapy (docetaxel…
- Trial name
- SAPPHIRE (NCT02019277)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 13 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.